



6. Ulusal CERRAHI ONKOLOJİ KONGRESİ
 24 - 27 Şubat 2022 | Gloria Golf Resort - ANTALYA

DR. MUSTAFA KARACA
 SAĞLIK BİLİMLERİ ÜNİVERSİTESİ TIP FAKÜLTESİ
 ANTALYA EĞİTİM VE ARAŞTIRMA HASTANESİ
 BİLEŞKE TÜMÖRLERİNDE ONKOLOJİK TEDAVİ









Evre	Görülme sıklığı	5 yıllık yaşam
I	%18	%50
II	%16	%30
III	%36	%10-15
IV	%30	%3-5


Kişiselleştirilmiş Tedavi

- HER2 amplification (IHC/ISH)
- MSI-H (PCR/NGS) or dMMR (IHC)
- PD-L1 elevation (IHC)

ÖGB Neoadjuvan Tedavi



- Neoadjuvan tedavi sonuçları tatmin edici
- Acaba karşı kolda adjuvan tedavi olsa idi sonuçlar değişir mi?



İdeal Neoadjuvan Kemoterapi Rejimi Nedir?

İdeal Neoadjuvan Kemoterapi Rejimi Ne Olmalı? FLOT4 TRIAL

Mide veya gastroözofageal bileşke (Tip I-III) adenokarsinom

- Operabl
- cT2-4 / cNany / cM0 veya
- cTany / cN+ / cM0

R

n:716

FLOT x 4 - Cerrahi - FLOT x 4

n:356

Primary endpoint OS (ITT)

ECF/ECX x 3 - Cerrahi - ECF/ECX x 3

n:360

Stratification: ECOG (0 or 1 vs. 2), location of primary (GEI type I vs. type II/III vs. stomach), age (< 60 vs. 60- 69 vs. ≥70 years) and nodal status (cN+ vs. cN-).


Al-Batran SE et al, Lancet. 2019 May 11;393(10184):1948-1957

FLOT4 TRIAL: Sonuçlar







	ECF/ECF n: 360	FLOT n: 356	p	
Cerrahi rezeksiyon	%87	%94	0.001	FLOT kemoterapisi ARTTIRIYOR ... - Cerrahi rezeksiyon oranını - R0 rezeksiyon oranını
R0 rezeksiyon	%77	%84	0.011	
Cerrahi komplikasyon	%55	%55	-	
90 günlük mortalite	%8	%5	-	FLOT kemoterapisi ETKİLEMIYOR ... - Cerrahi morbiditeyi - Cerrahi mortaliteyi
	ECF/ECF n: 360	FLOT n: 356	p	
ypT stage ≤T1	53 (%15)	88 (%25)	0.001	FLOT kemoterapisi patolojik olarak downstaging sağlıyor
ypN0 stage	146 (%41)	174 (%49)	0.029	






Al-Batran SE et al, Lancet. 2019 May 11;393(10184):1948-1957


FLOT4 TRIAL: Sağkalım



	ECF/ECF	FLOT		ECF/ECF	FLOT
PFS					
2 yıllık	%43	%53			
3 yıllık	%37	%46			
5 yıllık	%31	%41			
OS					
2 yıllık	%59	%68			
3 yıllık	%48	%57			
5 yıllık	%36	%45			







	KT	KRT
ÖGB / Dista özefagus	☑ 4 çalışma (Adenokarsinom)	☑ 1 çalışma (SCC + Adeno)
Güncel ajanların kullanımı	☑ FLOT	☑ Taxan-platin
Hedefe yönelik tedavilerin yeri	☑ Her-FLOT ☑ PETRARCA/FLOT6	☑ 1 çalışma negatif

	KT	KRT
pCR	%5-20	☑ %15-25
R0 rezeksiyon	%80-90	%90
Toksosite: ÖGB	Yönetilebilir	Yönetilebilir

Oligometastatik ÖGB Tümörler de Tedavi

Oligometastatik hastalıkta perioperatif KT (FLOT)


ASCO Oral Sesi 1 - Oral Presentation
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer
 The AIO-FLOT3 Trial


Poster to be presented at the 2021 ASCO Meeting, Abstract 255

Primary Objective: To compare overall survival (OS) between patients receiving neoadjuvant chemotherapy followed by resection (FLOT group) versus resection alone (control group) in patients with limited metastatic gastric or gastroesophageal junction cancer.

Study Design: Prospective, randomized, controlled, phase III trial.

Study Population: Patients with limited metastatic gastric or gastroesophageal junction cancer, Eastern Cooperative Oncology Group (ECOG) performance grade 0-2, Eastern Cooperative Oncology Group (ECOG) performance grade 0-2, ECOG performance grade 0-2, ECOG performance grade 0-2.








ÖGB Tümlörler de Devam Eden Çalışmalar

KEYNOTE-585: Phase III study of perioperative chemotherapy with or without pembrolizumab for gastric cancer


Yung-Jue Bang ¹, Eric Van Cutsem ², Charles S Fuchs ³, Atsushi Ohtsu ⁴, Josep Tabernero ⁵, David H Ilson ⁶, Woo Jin Hyung ⁷, Vivian E Strong ⁸, Thorsten Oliver Goetze ⁹, Takaki Yoshikawa ¹⁰, Laura H Tang ⁸, Peggy May Tan Hwang ¹¹, Nancy Webb ¹¹, David Adelberg ¹¹, Kohei Shitara ⁸



Ne kadar başarılı bir neoadjuvan tedavi,o kadar başarılı bir cerrahi ve uzamış sağkalım.



Kemoterapi&Kemoradyoterapi



TEŞEKKÜRLER

The one who knows more, may decide better